Ketamine Treatment for Depression: Does It Work?

Depression that hasn't responded to a standard antidepressant is one of the most common reasons people search out ketamine therapy, and the question behind that search is almost always the same: does it actually work? The honest answer is that ketamine and its FDA-approved cousin, esketamine (Spravato), have a real, clinically documented effect on depression for a meaningful share of patients — particularly those who haven't improved on two or more antidepressant trials. It isn't a cure, it doesn't work for everyone, and the evidence base, while substantial, is younger than the decades of data behind SSRIs. This guide lays out what's actually established, who tends to benefit, what a course of treatment looks like, and where the evidence runs thin — so you can walk into a conversation with a psychiatric provider with realistic expectations instead of marketing claims.

What the Research Shows

The single most consistent finding across ketamine depression research is speed. Standard oral antidepressants — SSRIs, SNRIs, and related classes — typically require four to six weeks of daily dosing before a clinician can tell whether they're working, and many patients cycle through more than one before finding an effective option. Ketamine works through a different mechanism, and in both academic clinical trials and everyday clinical practice, it can produce a measurable shift in depressive symptoms within hours to a few days of a single treatment. That rapid-acting property is what first drew psychiatric researchers to study ketamine for depression starting in the late 1990s and 2000s, well before esketamine's 2019 FDA approval, and it remains the treatment's most clinically important feature — particularly for patients whose symptoms are severe or urgent enough that waiting six weeks to find out if a medication works isn't a realistic option.

That timing difference isn't just a convenience. For a patient in active crisis, six weeks is a long time to wait to find out whether a medication will work, and every week without relief carries real risk. Ketamine's rapid-acting profile is part of why the FDA's second esketamine approval specifically covers depressive symptoms in adults with suicidal thoughts, used alongside an oral antidepressant — a population where fast-acting relief carries clinical weight beyond convenience. It's also why ketamine is sometimes discussed as a bridge treatment: something that can stabilize a patient more quickly while a longer-acting antidepressant has time to take full effect.

Esketamine (Spravato) carries the strongest formal evidence of the two, since it went through the randomized, placebo-controlled trial process the FDA requires for drug approval — the TRANSFORM and SUSTAIN trial programs — and was approved specifically for treatment-resistant depression in 2019, with a later approval covering depressive symptoms in adults with suicidal thoughts. Generic IV and IM ketamine has a longer research history but sits in a different regulatory lane: most of the published evidence comes from investigator-initiated academic studies rather than the pharmaceutical-sponsored trials that support a drug approval, which is part of why it remains an off-label use despite a substantial body of peer-reviewed research. Off-label doesn't mean unproven — it reflects how differently an FDA-approved drug and an older generic medication used outside its original indication move through the regulatory and publication system.

Where the evidence is more honest than clinic marketing often suggests: response isn't universal, effects from a single treatment tend to fade over days to weeks without continued dosing, and most of the strongest data covers short- to medium-term outcomes rather than years of maintenance treatment. Researchers are still working out optimal dosing intervals, which patients are most likely to sustain a response, and how ketamine performs against other rapid-acting options over the long run. Reading ketamine research honestly means holding both things at once — a real, replicated effect for many patients, and a research base that's still younger and narrower than decades-old antidepressant classes.

Who Ketamine Helps Most: Treatment-Resistant Depression

Ketamine and Spravato's clearest evidence and FDA labeling both center on treatment-resistant depression — depression that hasn't adequately improved after two or more antidepressant trials at an adequate dose and duration. That's a specific clinical definition, not a vague sense that "nothing has worked," and it's the population studied in the pivotal Spravato trials and in most of the academic ketamine research. Patients who fit that definition, especially those who've tried multiple medication classes without relief, are the group with the strongest documented reason to consider ketamine treatment.

That doesn't mean ketamine is reserved only for the most severe or longest-standing cases. Some patients pursue it earlier in their treatment history because of how they weigh speed, side-effect profile, or a strong preference to avoid another months-long medication trial — that's a conversation to have directly with a psychiatric provider who knows your history, not something a self-assessment online can settle. For general major depressive disorder without the treatment-resistant history, and for the practical question of finding a clinic, see the ketamine therapy for depression clinic directory.

Determining whether someone actually meets the treatment-resistant threshold isn't something a patient works out alone. It typically means documenting which medications were tried, at what doses, for how long, and how the patient responded — information a psychiatric provider reviews carefully before recommending ketamine or Spravato over another medication trial. Many patients also carry co-occurring diagnoses, such as anxiety alongside depression, and a full history helps a prescriber judge whether ketamine's dissociative effects are likely to be well tolerated or add complexity to an already complicated clinical picture.

IV Ketamine for Depression

IV ketamine for depression is the most studied format outside Spravato and remains the default at many mental-health clinics. A clinician sets the dose by body weight and controls the infusion rate in real time over roughly 40 to 60 minutes, which gives more moment-to-moment adjustment than a fixed nasal-spray dose. It's prescribed off-label for depression — the FDA approval covers only anesthetic use — so it's typically self-pay, and a standard induction series runs six infusions over two to three weeks. For the full mechanics of what a session involves and how it's dosed, see the IV ketamine infusion treatment page; this article focuses on whether and for whom it works, not the delivery details.

Esketamine (Spravato) for Depression

Esketamine — the nasal-spray formulation marketed as Spravato — is one mirror-image molecule isolated from ketamine, and it's the only ketamine-derived option with direct FDA approval for depression. That regulatory status is the practical reason many patients start there: it's more consistently covered by insurance with prior authorization, and it must be administered at a REMS-certified clinic under roughly two hours of observation, which built monitoring directly into the approval. Its efficacy evidence comes from the pivotal trials that supported approval rather than the mixed academic-study base behind generic IV ketamine. For dosing schedules, cost, and how it compares practically to IV ketamine, see the Spravato (esketamine) treatment page and the direct IV ketamine vs. Spravato comparison.

How Does Ketamine Work for Depression?

At the doses used for depression, ketamine blocks NMDA glutamate receptors in the brain — a different target than the serotonin and norepinephrine systems SSRIs and SNRIs act on. That blockade sets off downstream changes researchers describe as encouraging new synaptic connections, which is the leading explanation for why ketamine can produce mood improvement on a timescale of hours rather than weeks. This is a brief summary, not the full picture — the pharmacology, including why Spravato and generic ketamine act on slightly different receptor profiles, is its own topic covered in more depth in a dedicated science-focused guide on this site.

Other Ketamine Formats for Depression

IV infusion and Spravato are the two formats with the most direct depression-specific evidence, but they're not the only ways clinics deliver ketamine. IM (intramuscular) injection gives a similar drug exposure without an IV line, though with less real-time dose control. Oral ketamine troches, typically dispensed through telehealth programs for at-home use, produce lower peak blood levels and are generally considered the least intensive format, with correspondingly less direct evidence specific to depression outcomes. Compare every treatment format side by side, including which one a given clinic near you actually offers.

What a Course of Treatment Looks Like

Ketamine for depression is delivered as a structured course, not a single visit. A typical IV protocol starts with an induction series — commonly six infusions over two to three weeks — followed by periodic booster sessions spaced out based on how long a patient's response lasts. Spravato follows a comparable arc: twice-weekly dosing for the first month, tapering to weekly and then biweekly or monthly maintenance. Exact schedules vary by clinic, diagnosis, and individual response, and dosage and session-count questions are covered in full in a dedicated guide on how many ketamine treatments you actually need for depression.

How Long Do the Effects Last?

Durability is one of the more honest caveats in ketamine research. A single infusion or dose can produce a mood improvement that peaks within days and then fades without follow-up treatment, which is exactly why induction series and maintenance dosing exist — the goal is to build and then sustain a response rather than treat once and stop. How long relief lasts between sessions varies considerably from patient to patient, and it's one of the main things a prescriber tracks across a treatment course to decide how to space maintenance visits. Consistency matters more than most patients expect — skipping or significantly delaying doses within an induction series can blunt the cumulative effect clinicians are aiming for, which is part of why clinics ask patients to commit to the full initial schedule before judging whether treatment is working. Patients considering ketamine or Spravato for bipolar depression specifically should also review the added precautions around mood-switch risk covered in a dedicated ketamine for bipolar depression guide.

When Ketamine Doesn't Work

Ketamine isn't effective for every patient who tries it, and that's worth saying plainly rather than burying in a disclaimer. Some patients complete a full induction series and see no meaningful change. Others respond initially but the benefit fades faster than a sustainable maintenance schedule can manage. Some can't tolerate the dissociative side effects at an effective dose well enough to continue treatment, and some are ruled out entirely during screening because of cardiovascular history, a personal history of psychosis, or other contraindications a prescriber checks before the first session. None of that means the treatment failed as a category — it means, like every depression treatment, individual response varies, and a non-response is real clinical information that should shape what a patient and prescriber try next, not a reason to assume nothing will help.

Evidence-Quality Honesty

It's worth being direct about what's solid and what's still developing. Solid: ketamine's rapid-acting effect on depressive symptoms is well replicated across multiple trial designs and research groups, and esketamine's efficacy for treatment-resistant depression cleared the FDA's drug-approval bar, which is a high evidentiary standard. Still developing: long-term outcomes data beyond a year or so of treatment is thinner than for decades-old antidepressant classes, optimal maintenance intervals aren't fully standardized across the field, and much of the generic IV ketamine literature — while substantial — is investigator-initiated academic research rather than the large, industry-funded trials that back an FDA approval. A clinic that presents ketamine as a guaranteed fix, or quotes a specific success percentage without citing where that number comes from, isn't representing the evidence accurately. Ask any clinic you're considering what published data supports their specific protocol, and treat response-rate claims in marketing material with real skepticism.

One additional wrinkle researchers discuss openly: ketamine's dissociative effects make it hard to fully blind a placebo-controlled trial, since patients and sometimes clinicians can often tell whether they received the active drug based on how it feels. Some trials have used an active placebo — a different sedating drug — to address this, but the blinding challenge is a real, acknowledged limitation across much of the field's controlled-trial literature rather than a flaw unique to any one study. It's part of why the field leans on converging evidence from multiple trial designs and real-world outcomes data rather than any single study.

If you're ready to compare options, most of the clinics in this directory list which formats they offer, whether they accept insurance, and pricing when a clinic publishes it — see the full ketamine clinic directory to find providers near you. For a straightforward cost breakdown across every format, see how much ketamine therapy costs, and if you're still weighing ketamine against another rapid-acting option, see ketamine therapy vs. TMS for depression. Before committing to any provider, it's also worth reviewing ketamine's side effects and risks for your specific medical history.

Frequently Asked Questions

None of this replaces an evaluation with a licensed psychiatric provider who can review your treatment history and medical background. It's meant to help you ask sharper questions of a prospective clinic, not to diagnose or recommend treatment on its own.

Sources: FDA prescribing information and pivotal trial data for esketamine (Spravato), including the TRANSFORM and SUSTAIN trial programs; peer-reviewed academic literature on IV ketamine for treatment-resistant depression. Informational only — not medical advice. Talk with a licensed clinician about your specific diagnosis and history before starting treatment.